10/09/2026
CARDIOTOXICITY IN BREAST CANCER CARE
As breast cancer survival improves and people live longer after treatment, protecting heart and cardiovascular health has become increasingly important. Some cancer treatments may cause cardiovascular side effects during treatment or in the longer term. Understanding these effects, known as cardiotoxicity, is the first step towards recognising and managing the risk.
On 9 September, we were pleased to welcome dr. Antonella Moreo, cardiologist and EUROPA DONNA Board Member, and Professor Ketti Mazzocco, Director of the Psycho-Oncology, Decision-Making and Health Promotion Unit at the European Institute of Oncology in Milan, for the roundtable “Cardiotoxicity in Breast Cancer Care: From Individual Vulnerability to Early Detection.”
Dr Moreo explained that cardiotoxicity can affect the heart and cardiovascular system in different ways and may sometimes develop without noticeable symptoms.
Every patient has a different cardiovascular risk profile. Monitoring should therefore consider individual factors, including age, existing health conditions and lifestyle, alongside the type, dose, combination and duration of cancer treatment. Early detection can enable healthcare teams to intervene before more serious problems develop, while cardiovascular follow-up may remain important even after cancer treatment has ended.
Professor Mazzocco explored how psychological, behavioural and social vulnerability may contribute to cardiotoxicity risk alongside traditional clinical factors. She also presented findings from the EU-funded CARDIOCARE project, on whose External Advisory Board EUROPA DONNA serves.
The project followed more than 600 breast cancer patients aged 60 and over, combining clinical and biomarker data with information on lifestyle, psychological wellbeing and behaviour, as well as data collected through wearable devices. The research identified a baseline vulnerability profile involving factors such as perceived stress, optimism, diet and heart-rate variability.
By bringing these different dimensions together, CARDIOCARE aims to support a more integrated and person-centred approach to predicting and managing cardiotoxicity risk.
The proposed pathway is clear: screen, profile, stratify, monitor and personalise. The goal is not more tests for everyone, but the right monitoring and support, at the right time, for the right person:
❤️ What is my heart-health baseline before treatment?
❤️ Which symptoms should I report during treatment?
❤️ What monitoring plan is appropriate for my individual risk?
❤️ What psychological and lifestyle support is available?
Thank you to Dr Moreo, Professor Mazzocco and all the advocates who contributed to this important conversation.